Appointment of Non-Executive Director

RNS Number : 1501R

Futura Medical PLC

07 March 2016

 

For immediate release

7 March 2016

Futura Medical plc

("Futura" or the "Company")

Appointment of Non-Executive Director

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce the appointment of Ken James, the former head of consumer healthcare R&D at GlaxoSmithKline plc ("GSK"), as a Non-Executive Director, with effect from 31 March 2016.

Mr James has more than 40 years' experience of healthcare R&D, having joined one of GSK's predecessor businesses, Beecham Products, in 1973. In 2006, he was appointed as Senior Vice President, GSK Consumer Healthcare R&D, with worldwide responsibility for consumer healthcare R&D, including medical and regulatory affairs and R&D sites spanning the globe.  Mr James, who recently retired from his role at GSK, has a proven track record, having brought over 200 innovative consumer healthcare products to market across multiple geographies whilst heading GSK Consumer Healthcare R&D.

Commenting on his appointment to Futura Medical, Ken James said: "I have always believed that scientific differentiation is a clear point of competitive advantage in the consumer healthcare sector. In Futura, I see a company with good technology and a product portfolio with considerable potential. I look forward to bringing to Futura my 40-plus years' experience in the commercialisation of healthcare products."

James Barder, Futura Medical's Chief Executive, said: "I am delighted to welcome Ken James to Futura's Board as a Non-Executive Director. As the former head of R&D at GSK consumer healthcare, his experience of the development and commercialisation of over-the-counter and consumer products is unparalleled. We very much look forward to his contribution to Futura."

Additional information:

Kenneth William James, aged 63 years, holds no shares in Futura. There are no further disclosures to be made in relation to Mr James under Schedule Two paragraphs (g) and (i) or Rule 17 of the AIM rules.

For further information please contact:

Futura Medical plc
James Barder, Chief Executive	Tel: [phone]
Email to: [e-mail]	www.futuramedical.com
N+1 Singer (Nominated Adviser and Broker)
Aubrey Powell / Liz Yong / Tom Smale Corporate Finance	Tel:[phone]
For media enquiries please contact:
Buchanan
Mark Court / Sophie Cowles / Stephanie Watson	Tel: [phone]

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

 

END

 

 

BOAEZLFBQXFFBBL